Immunosuppressants - Eastern Africa

In Eastern Africa, the Immunosuppressants market is anticipated to achieve a revenue of US$61.16m in 2024.
The market is projected to display a steady annual growth rate (CAGR 2024-2029) of 15.69%, leading to a market volume of US$126.80m by 2029.
When compared globally, United States is expected to generate the highest revenue, with US$35.47bn in 2024.
Eastern Africa is experiencing a growing demand for immunosuppressants due to an increase in organ transplant surgeries.

Definition:
The Immunosuppressants market covers drugs which suppress the immune response. These remedies are used in different therapy areas, mainly to treat auto-immune diseases, such as psoriasis. Anti-rejection drugs administered after organ transplantations are also included in this market. Monoclonal antibodies are an important type of immunosuppressant.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Johnson & Johnson, Sanofi, Novartis

Drugs to suppress the immune response
Immunosuppressants to treat auto-immune diseases, such as psoriasis
Anti-rejection drugs

Multiple sclerosis drugs
Anti-rheumatic drugs
Immuno-oncology drugs
Antivirals
Antibiotics
Corticosteroids
HIV drugs

The Immunosuppressants market in Eastern Africa has been experiencing significant growth in recent years.

Customer preferences: As the population in Eastern Africa continues to grow and age, there has been an increase in the prevalence of autoimmune diseases and transplant surgeries. This has led to a rise in demand for immunosuppressant drugs, which are used to prevent the body from rejecting transplanted organs or to treat autoimmune diseases.

Trends in the market: One of the major trends in the immunosuppressants market in Eastern Africa is the increasing availability of generic drugs. This has led to greater affordability and accessibility of these drugs, particularly in low-income countries in the region. In addition, there has been a shift towards more targeted immunosuppressant therapies, which are designed to be more effective while minimizing side effects.

Local special circumstances: However, there are also challenges facing the immunosuppressants market in Eastern Africa. One of the main issues is the lack of healthcare infrastructure and trained healthcare professionals in many countries in the region. This can make it difficult for patients to access the drugs they need, as well as limit the ability of pharmaceutical companies to market and distribute their products effectively.

Underlying macroeconomic factors: Another factor influencing the immunosuppressants market in Eastern Africa is the overall economic development of the region. As countries in the region continue to grow and develop, there is likely to be an increase in healthcare spending and investment in healthcare infrastructure. This could lead to greater demand for immunosuppressant drugs, as well as more opportunities for pharmaceutical companies to enter the market. However, political instability and economic uncertainty in some countries could also pose challenges for the market in the future.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.